Apotex Bags First Biosimilar Neulasta, Plans To Undercut Amgen In Canada By 25%

 
• By Ian Schofield

Apotex is hoping to sell its biosimilar version of Amgen’s Neulasta at a 25% discount in Canada after gaining approval there in what seems to be a world first. Might the Canadian OK help unblock the path to approval in the US and the EU?

Approved
Apotex has received approval in Canada for its biosimilar pegfilgrastim

More from Biosimilars

More from Biosimilars & Generics